Acumen Pharmaceuticals (NASDAQ:ABOS) Stock Quotes, Forecast and News Summary

Q: What sector and industry does Acumen Pharmaceuticals (ABOS) operate in?

Acumen Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Acumen Pharmaceuticals Stock (NASDAQ: ABOS) stock price, news, charts, stock research, profile.

Open	$1.40
Close	$1.39
Volume / Avg.	402.19K / 316.16K
Day Range	$1.36 - $1.43
52 Wk Range	1.28 - 5.09
Market Cap	$83.51M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	37
Short Interest	4.11%
Days to Cover	5.94

Recent News

Halozyme's ENHANZE Product Gets New Patent Grant in EU

Halozyme Therapeutics (NASDAQ: HALO) announced that it has been granted a new patent in the EU that covers the ENHANZE rHuPH20 product, which is produced using the company's proprietary ENHANZE manufacturing methods.

Zacks

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

Oct 24

Nov 24

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.2

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	$1.40
Close	$1.39
Volume / Avg.	402.19K / 316.16K
Day Range	$1.36 - $1.43
52 Wk Range	1.28 - 5.09
Market Cap	$83.51M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	37
Short Interest	4.11%
Days to Cover	5.94

About Acumen Pharmaceuticals Inc

Sector

Health Care

Industry

Biotechnology

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Acumen Pharmaceuticals (ABOS) stock?

You can purchase shares of Acumen Pharmaceuticals (NASDAQ:ABOS) through any online brokerage.

View our list of the best stock brokerages

Who are Acumen Pharmaceuticals (ABOS) competitors?

Other companies in Acumen Pharmaceuticals’s space includes: Galectin Therapeutics (NASDAQ:GALT), Adverum Biotechnologies (NASDAQ:ADVM), Inozyme Pharma (NASDAQ:INZY), FibroGen (NASDAQ:FGEN) and Citius Oncology (NASDAQ:CTOR).

What is the forecast, or price target, for Acumen Pharmaceuticals (ABOS) stock?

Acumen Pharmaceuticals has a consensus price target of $12.25.

What is the current price for Acumen Pharmaceuticals (ABOS)?

The stock price for Acumen Pharmaceuticals (NASDAQ: ABOS) is $1.39 last updated February 21, 2025 at 4:02 PM EST.

Does Acumen Pharmaceuticals (ABOS) pay a dividend?

There are no upcoming dividends for Acumen Pharmaceuticals.

When is Acumen Pharmaceuticals (NASDAQ:ABOS) reporting earnings?

Acumen Pharmaceuticals’s Q1 earnings are confirmed for Tuesday, May 13, 2025.

Is Acumen Pharmaceuticals (ABOS) going to split?

There is no upcoming split for Acumen Pharmaceuticals.

What sector and industry does Acumen Pharmaceuticals (ABOS) operate in?

Acumen Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Comments

Acumen Pharmaceuticals

Acumen Pharmaceuticals (ABOS) Forecast